|
GB8311018D0
(en)
|
1983-04-22 |
1983-05-25 |
Amersham Int Plc |
Detecting mutations in dna
|
|
US4998617A
(en)
|
1986-09-15 |
1991-03-12 |
Laura Lupton Inc |
Facial cosmetic liquid make up kit
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US6270961B1
(en)
|
1987-04-01 |
2001-08-07 |
Hyseq, Inc. |
Methods and apparatus for DNA sequencing and DNA identification
|
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
FR2650840B1
(fr)
|
1989-08-11 |
1991-11-29 |
Bertin & Cie |
Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
US6004744A
(en)
|
1991-03-05 |
1999-12-21 |
Molecular Tool, Inc. |
Method for determining nucleotide identity through extension of immobilized primer
|
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
|
US5952172A
(en)
|
1993-12-10 |
1999-09-14 |
California Institute Of Technology |
Nucleic acid mediated electron transfer
|
|
US5968740A
(en)
|
1995-07-24 |
1999-10-19 |
Affymetrix, Inc. |
Method of Identifying a Base in a Nucleic Acid
|
|
JP2000508912A
(ja)
|
1996-04-19 |
2000-07-18 |
スペクトラ バイオメディカル，インコーポレイテッド |
多型形態と複数の表現型との相関付け
|
|
JP2894445B2
(ja)
|
1997-02-12 |
1999-05-24 |
日本たばこ産業株式会社 |
Ｃｅｔｐ活性阻害剤として有効な化合物
|
|
AU9381598A
(en)
|
1997-09-10 |
1999-03-29 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Method of amplifying dna and rna mismatch cleavage products
|
|
US6197786B1
(en)
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
|
ES2265945T3
(es)
|
1999-06-04 |
2007-03-01 |
Consejo Superior De Investigaciones Cientificas |
Plantas, semillas y aceites de girasol con un contenido alto de oleico y alto de estearico.
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
CO5271716A1
(es)
|
1999-11-30 |
2003-04-30 |
Pfizer Prod Inc |
Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
|
|
WO2003015708A2
(en)
|
2001-08-18 |
2003-02-27 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
|
US20060141493A1
(en)
|
2001-11-09 |
2006-06-29 |
Duke University Office Of Science And Technology |
Atherosclerotic phenotype determinative genes and methods for using the same
|
|
US20040180370A1
(en)
|
2003-01-27 |
2004-09-16 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetic diagnosis of alcoholism subtypes
|
|
WO2004082675A1
(en)
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
|
|
TWI494102B
(zh)
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
US7276608B2
(en)
|
2003-07-11 |
2007-10-02 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
|
KR20060080214A
(ko)
|
2003-09-26 |
2006-07-07 |
니뽄 다바코 산교 가부시키가이샤 |
잔여 리포프로테인 생산 저해 방법
|
|
US7517900B2
(en)
|
2003-10-10 |
2009-04-14 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
RU2006126122A
(ru)
|
2003-12-19 |
2008-01-27 |
Бристол-Маерс Сквибб Компани (Us) |
Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
|
|
PL1697371T3
(pl)
|
2003-12-19 |
2007-09-28 |
Bristol Myers Squibb Co |
Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
|
|
KR20070010151A
(ko)
|
2004-03-30 |
2007-01-22 |
사파이어 세라퓨틱스, 인크. |
성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
|
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
DK1828137T3
(da)
|
2004-12-18 |
2012-07-23 |
Bayer Pharma AG |
4-Cycloalkyl-substituerede tetrahydroquinolinderivater og deres anvendelse som medikamenter
|
|
CA2593793A1
(en)
|
2005-01-05 |
2006-07-13 |
Medicure International Inc. |
Compounds and methods for regulating triglyceride levels
|
|
WO2006099142A2
(en)
*
|
2005-03-10 |
2006-09-21 |
The Trustees Of Boston University |
Prognostic method for vascular diseases
|
|
JP2006288279A
(ja)
|
2005-04-11 |
2006-10-26 |
Otsuka Pharmaceut Co Ltd |
出血時間延長傾向判定方法
|
|
CA2612142A1
(en)
|
2005-07-01 |
2007-01-11 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
KR20080059233A
(ko)
|
2005-10-21 |
2008-06-26 |
노파르티스 아게 |
레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
|
|
US7435849B2
(en)
|
2005-10-31 |
2008-10-14 |
Hoffmann-La Roche Inc. |
Process for the production of acid chlorides
|
|
EP1948599A1
(en)
|
2005-11-08 |
2008-07-30 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
|
WO2007071824A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein -cholesterol (hdl-c)
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
EP1935867A1
(en)
|
2006-12-20 |
2008-06-25 |
F. Hoffmann-La Roche Ag |
Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
|
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
EP2150520B1
(en)
|
2007-04-25 |
2012-10-31 |
F. Hoffmann-La Roche AG |
Novel process for the preparation of acid chlorides
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
US20090105124A1
(en)
|
2007-08-23 |
2009-04-23 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
CN101981001B
(zh)
|
2008-04-04 |
2016-06-08 |
弗·哈夫曼-拉罗切有限公司 |
制备环己烷甲酸衍生物的新方法
|
|
BRPI0911170B1
(pt)
|
2008-04-04 |
2018-05-29 |
F. Hoffmann-La Roche Ag |
Processo para a preparação de derivados do ácido ciclo-hexanocarboxílico via o correpondente derivado de ciclo-hexanocarboxamida
|
|
EP2297081B1
(en)
|
2008-06-17 |
2017-03-08 |
F. Hoffmann-La Roche AG |
1-(2-ethyl-butyl)-cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
WO2010056910A2
(en)
|
2008-11-12 |
2010-05-20 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
JP5538423B2
(ja)
|
2008-12-08 |
2014-07-02 |
エフ．ホフマン−ラ ロシュ アーゲー |
薬物の併用投与
|
|
NZ720946A
(en)
|
2009-04-29 |
2017-09-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
TWI450896B
(zh)
|
2009-06-30 |
2014-09-01 |
Lilly Co Eli |
反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
|
|
US20110004011A1
(en)
|
2009-07-01 |
2011-01-06 |
Declan Costello |
Novel process
|
|
CA2770980A1
(en)
|
2009-07-15 |
2011-01-20 |
Roger Y. Tsien |
Peptides whose uptake in cells is controllable
|
|
JP2013527148A
(ja)
|
2010-04-07 |
2013-06-27 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｃｅｔｐ発現の調節
|
|
EP2598158A4
(en)
*
|
2010-07-28 |
2014-03-12 |
Inst Cardiologie Montreal |
Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
|
|
KR20130100124A
(ko)
|
2010-09-16 |
2013-09-09 |
에프. 호프만-라 로슈 아게 |
신규 방법
|
|
PE20140018A1
(es)
|
2010-11-04 |
2014-01-31 |
Hoffmann La Roche |
Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica
|
|
WO2012069087A1
(en)
|
2010-11-25 |
2012-05-31 |
Mediasuccess Gmbh |
Automatic text generation
|
|
MX2013006031A
(es)
|
2010-12-08 |
2013-07-15 |
Hoffmann La Roche |
Formulacion liposomal de dalcetrapib.
|
|
EP2651882B1
(en)
|
2010-12-16 |
2018-11-14 |
F.Hoffmann-La Roche Ag |
Process for the preparation of aromatic thiol derivatives by hydrogenation of disulfides
|
|
US20140044668A1
(en)
*
|
2011-02-15 |
2014-02-13 |
The Ohio State University |
Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs
|
|
KR20140006879A
(ko)
|
2011-02-17 |
2014-01-16 |
에프. 호프만-라 로슈 아게 |
고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
|
|
US9541565B2
(en)
|
2011-04-08 |
2017-01-10 |
Zora Biosciences Oy |
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
CN103502820B
(zh)
*
|
2011-04-08 |
2016-09-07 |
佐拉生物科学公司 |
用于他汀引发的肌肉毒性的灵敏检测的生物标志物
|
|
WO2012149473A2
(en)
*
|
2011-04-29 |
2012-11-01 |
Children's Hospital & Research Center At Oakland |
Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
|
|
US20120301439A1
(en)
|
2011-05-24 |
2012-11-29 |
Washington University |
Inhibition of choroidal neovascularization
|
|
US8975438B2
(en)
|
2011-07-13 |
2015-03-10 |
Hoffmann-La Roche Inc. |
Process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
AR089853A1
(es)
|
2012-02-01 |
2014-09-24 |
Boehringer Ingelheim Int |
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
|
|
JP6080226B2
(ja)
|
2012-03-06 |
2017-02-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
|
|
BR112014027047A2
(pt)
|
2012-04-30 |
2017-06-27 |
Hoffmann La Roche |
nova formulação
|
|
MX351059B
(es)
|
2012-08-17 |
2017-09-29 |
Laboratorios Senosiain S A De C V Star |
Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
|
|
PL2978859T3
(pl)
*
|
2013-03-27 |
2018-10-31 |
F.Hoffmann-La Roche Ag |
Markery genetyczne do przewidywania reakcji na terapię
|
|
JP6539661B2
(ja)
|
2013-12-19 |
2019-07-03 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
眼疾患の処置において使用するためのｃｅｔｐモデュレーター
|
|
GB201401617D0
(en)
*
|
2014-01-30 |
2014-03-19 |
Helperby Therapeutics Ltd |
Novel combination and use
|
|
EP3795695A1
(en)
|
2014-07-30 |
2021-03-24 |
F. Hoffmann-La Roche AG |
Genetic markers for predicting responsiveness to therapy
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
MX2021001520A
(es)
|
2018-08-09 |
2021-05-27 |
Dalcor Pharma Uk Ltd Leatherhead Zug Branch |
Metodos para retardar la ocurrencia de diabetes tipo 2 de nuevo inicio y para desacelerar el progreso de y tratamiento de la diabetes tipo 2.
|